Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7156 to 7170 of 8224 results

  1. Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

    Discontinued Reference number: GID-TA10707

    Technology appraisal guidance
    Discontinued

  2. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued Reference number: GID-TA10709

    Technology appraisal guidance
    Discontinued

  3. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  4. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  5. Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

    Discontinued Reference number: GID-TA10737

    Technology appraisal guidance
    Discontinued

  6. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

    Technology appraisal guidance
    Discontinued

  7. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  8. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued Reference number: GID-TA10750

    Technology appraisal guidance
    Discontinued

  9. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development Reference number: GID-TA10758 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  11. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued Reference number: GID-TA10767

    Technology appraisal guidance
    Discontinued

  12. Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

    Discontinued Reference number: GID-TA10768

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]

    In development Reference number: GID-TA10780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued Reference number: GID-TA11205

    Technology appraisal guidance
    Discontinued

  15. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued Reference number: GID-TA11206

    Technology appraisal guidance
    Discontinued